Fierce Health IT January 14, 2020
UPMC has invested more than $800 million in its entrepreneurial efforts to date, primarily in digital solutions, which have returned more than $1.5 billion, officials said.
University of Pittsburgh Medical Center’s venture capital arm is committing $1 billion in investments toward developing new drugs, diagnostics and devices by 2024.
The investments will be targeted to complement the work already underway in Pittsburgh, including a $200 commitment toward an immunotherapy-focused partnership with the University of Pittsburgh, officials said in a statement.
UPMC Enterprises’ initial focus has been on the use of immunotherapies for cancer, transplantation and diseases related to aging. But the group is expanding to look at retinal and respiratory diseases, autoimmune diseases and neuroinflammation.
“The common link among our...